Aerosolized Surfactant for Preterm Infants with Respiratory Distress Syndrome by Brasher, Mandy et al.
University of Kentucky 
UKnowledge 
Pediatrics Faculty Publications Pediatrics 
6-10-2021 
Aerosolized Surfactant for Preterm Infants with Respiratory 
Distress Syndrome 
Mandy Brasher 
University of Kentucky, mandy.brasher@uky.edu 
Thomas M. Raffay 
Case Western Reserve University 
M. Douglas Cunningham 
University of Kentucky, doug.cunningham@uky.edu 
Elie G. Abu Jawdeh 
University of Kentucky, elie.abujawdeh@uky.edu 
Follow this and additional works at: https://uknowledge.uky.edu/pediatrics_facpub 
 Part of the Pediatrics Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Brasher, Mandy; Raffay, Thomas M.; Cunningham, M. Douglas; and Abu Jawdeh, Elie G., "Aerosolized 
Surfactant for Preterm Infants with Respiratory Distress Syndrome" (2021). Pediatrics Faculty 
Publications. 316. 
https://uknowledge.uky.edu/pediatrics_facpub/316 
This Review is brought to you for free and open access by the Pediatrics at UKnowledge. It has been accepted for 
inclusion in Pediatrics Faculty Publications by an authorized administrator of UKnowledge. For more information, 
please contact UKnowledge@lsv.uky.edu. 
Aerosolized Surfactant for Preterm Infants with Respiratory Distress Syndrome 
Digital Object Identifier (DOI) 
https://doi.org/10.3390/children8060493 
Notes/Citation Information 
Published in Children, v. 8, issue 6, 493. 
© 2021 by the authors 
This article is an open access article distributed under the terms and conditions of the Creative 
Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). 
This review is available at UKnowledge: https://uknowledge.uky.edu/pediatrics_facpub/316 
children
Review
Aerosolized Surfactant for Preterm Infants with Respiratory
Distress Syndrome
Mandy Brasher 1,*, Thomas M. Raffay 2 , M. Douglas Cunningham 1 and Elie G. Abu Jawdeh 1,*


Citation: Brasher, M.; Raffay, T.M.;
Cunningham, M.D.; Abu Jawdeh, E.G.
Aerosolized Surfactant for Preterm
Infants with Respiratory Distress
Syndrome. Children 2021, 8, 493.
https://doi.org/10.3390/
children8060493
Academic Editor: Dirk Bassler
Received: 27 May 2021
Accepted: 7 June 2021
Published: 10 June 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Pediatrics/Neonatology, College of Medicine, University of Kentucky,
Lexington, KY 40506, USA; doug.cunningham@uky.edu
2 Department of Pediatrics/Neonatology, College of Medicine, Case Western Reserve University,
Cleveland, OH 44106, USA; tmr12@case.edu
* Correspondence: mandy.brasher@gmail.com (M.B.); elie.abujawdeh@uky.edu (E.G.A.J.);
Tel.: +1-859-323-6117 (E.G.A.J.); Fax: +1-859-257-6066 (E.G.A.J.)
Abstract: Currently, the administration of surfactant to preterm infants with respiratory distress
syndrome (RDS) mainly relies on intratracheal instillation; however, there is increasing evidence
of aerosolized surfactant being an effective non-invasive strategy. We present a historical narrative
spanning sixty years of development of aerosolization systems. We also offer an overview of the
pertinent mechanisms needed to create and manage the ideal aerosolization system, with a focus on
delivery, distribution, deposition, and dispersion in the context of the human lung. More studies are
needed to optimize treatment with aerosolized surfactants, including determination of ideal dosages,
nebulizer types, non-invasive interfaces, and breath synchronization. However, the field is rapidly
evolving, and widespread clinical use may be achieved in the near future.
Keywords: aerosolized surfactant; nebulize; respiratory distress syndrome; preterm infants
1. Introduction
Respiratory distress syndrome (RDS) secondary to surfactant deficiency is a common
problem and major cause of morbidity and mortality in neonates, especially in preterm
infants [1]. Outcomes and management of RDS have improved significantly with the
discovery of exogenous surfactants and the refinement of instillation strategies. There are
currently multiple natural and synthetic exogenous surfactants with comparable benefits
and risks [2]. Intratracheal instillation, in various strategies, remains the most widely
accepted method of surfactant administration to infants with RDS [3,4]. However, there
is increasing evidence suggesting that supraglottic administration via aerosolization is
feasible and effective in preterm infants with RDS [5–8].
2. The Challenging Road towards Successful Clinical Application: Historical Narrative
The clinical success of aerosolized surfactants has been fraught with difficulty. For
more than six decades, many attempts to aerosolize an exogenous surface tension reduc-
ing agent have been reported. However, within the past decade, multiple reports have
demonstrated effective aerosol models for delivering exogenous surfactants in tandem
with non-invasive ventilatory support.
The first attempts of an aerosolized surfactant came in a preliminary study in 1964
by Robillard et al., who attempted to administer an aerosol of the synthetic surfactant
beta-gamma-dipalmitoyl-L-alpha-lecithin (DPL) to 11 infants with RDS [9]. The eight
infants who survived had a modest improvement in their retraction scores. Although
these results were not clinically significant, they provided optimism towards aerosolizing
surfactants. The second study of this era, Chu et al. in 1967, comprehensively explored an
aerosolized DPL via several methods [10]. Using a freon gas carrier, DPL was aerosolized
and administered to the excised lungs of 14 infants at autopsy (7 of whom carried the
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diagnosis of RDS and 7 with normal lungs), with no observed changes to lung elasticity.
Subsequently, DPL was aerosolized into the hood of 15 spontaneously breathing live
infants. Only half of the infants showed some improvement in their respiratory distress
after treatment. In retrospect, this particular form of synthetic surfactant is a rigid crystalline
gel at physiologic temperature and also does not have the advantage of surfactant proteins.
After these two studies, several decades passed, with advancements in the use of non-
invasive respiratory support and instilled surfactant for RDS.
Surfactant, as an aerosol, was revisited by Lewis et al. in 1991 [11]. In an effort to
distribute surfactant more uniformly throughout the lungs, Lewis et al. administered
aerosolized surfactant to premature lambs for comparison with instilled surfactant. All
groups still utilized an endotracheal tube with subsequent ventilator support, and the
aerosolized surfactant was released synchronized with inhalation. Lambs treated with
aerosolized surfactant demonstrated improvement in their ventilation on par with the
instilled surfactant group. Despite this match in clinical outcome, they estimated the dose
of aerosolized surfactant deposited in the lungs was only 2 mg/kg. This is markedly less
than the instilled surfactant dose of 50 mg/kg, with an estimated 19 mg/kg of surfactant
delivered to the lungs.
The promising results of the Lewis et al. lamb study were naturally followed by
a proliferation of animal studies, lung cast modeling, and occasional infant feasibility
studies. Some studies investigated different nebulizer types, such as Henry et al. in their
1996 study using ultrasonic nebulized surfactant in preterm lambs [12]. While they were
able to correlate aerosolized surfactant deposition with better-ventilated regions of lung,
the treated lambs did not show improvement in oxygenation. In 1998, Fok et al. also
utilized an ultrasonic nebulizer and were able to deliver high levels of surfactant in a
rabbit model but found only mediocre clinical improvement [13]. The best explanation
for this lack of clinical improvement despite adequate surfactant deposition is surfactant
inactivation by the high levels of heat generated by ultrasonic nebulizers.
Unique approaches were attempted to solve the dilemma of delivering effective
surfactant to the distal airways, such as the hydroscopic surfactant used in the 1996 rabbit
model by Ellyett et al. [14]. This “dried” surfactant would progressively become saturated
with water during transit, becoming heavier when in the distal airways to settle there. This
was preliminarily successful but not pursued further. In another case, a feasibility study of
20 infants used a specially modified nasopharyngeal tube placed behind the soft palate for
jet-nebulized surfactant, with improvement in respiratory outcomes [15].
At the turn of the century, Berggren et al. performed a clinical pilot study in Sweden
of nebulized surfactant therapy for neonatal RDS [16]. The study included 34 newborns
on continuous positive airway pressure (CPAP) placed into either a treatment group of
480 mg aerosolized poractant alfa via a jet nebulizer or CPAP alone. There were no adverse
events noted from aerosolization. However, there was also no documented benefit, with
no difference in respiratory outcomes between treatment and control groups, including
days on CPAP or need for mechanical ventilation (38% treated vs. 31% controls). Through
the 2000s, two new approaches emerged. First, lucinactant, a second-generation synthetic
surfactant comprised of two phospholipids, a fatty acid, and a synthetic surfactant protein
B (SP-B) peptide replacement, KL4, came to the forefront [5,17,18]. Unlike the surfactant
proteins in natural surfactants, the synthetic KL4 is more resistant to the aerosolization
process [19]. The second shift in the aerosolization process manifested as a new focus
on vibrating membrane nebulizers. Finer et al. in 2010 presented the combination of
prophylactic lucinactant and vibrating membrane nebulizers in a safety and feasibility
study of 17 infants [5]. The failure rate, defined as intubation, occurred less frequently in
infants receiving aerosolized lucinactant (29%) compared to historical controls.
Coming to the most recent years, deliberate combinations of nebulizers, surfactants,
and nasopharyngeal interfaces have emerged as a non-invasive approach to aerosolized
surfactants. Minocchieri et al. offered a blinded randomized controlled trial of 64 infants
in 2019 using the eFlow neonatal vibrating mesh nebulizer to administer poractant alfa
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via a dedicated nebulizer adapter [6]. They showed a decrease in intubation rates with a
relative risk reduction of 0.57 (95% CI: 0.34 to 0.94). The same year, Sood et al. presented
an uncontrolled 17 infant safety and feasibility pilot study using the MiniHeart Lo-Flo
jet nebulizer via short binasal prongs; the infants tolerated the treatments well, with
clinical improvement, as measured by heart rate, pCO2, and blood pH [7]. The most
robust example of the customized interface is the 2020 Cummings et al. study, which
included 457 infants randomized to standard of care (CPAP) or treatment with aerosolized
surfactant via a modified Solarys pneumatically driven nebulizer with the patient interface
in a pacifier shape [8]. This multicenter study included both preterm and term infants
with respiratory distress on CPAP support, with randomization within the first 12 h of life.
The study allowed multiple doses of aerosolized surfactant to be administered as per the
clinical team. The primary outcome was endotracheal intubation during the first 4 days
of life. There was a decrease in intubation in infants who received surfactant (RR: 0.51
(90% CI: 0.41–0.63)) compared to CPAP alone. The Cummings et al. study is the largest trial
that has investigated aerosolized surfactant. More studies, including a systematic review,
are currently underway that will provide more insight into the effectiveness of aerosolized
surfactant, including prevention of intubation and subsequent mechanical ventilation [20].
3. Nebulizers
The evolution and composition of nebulizers play an important role in the success of
aerosolized surfactants. There are three general categories of nebulizers, with subsequent
subtypes and modifications within each family. This includes jet nebulizers, ultrasonic
nebulizers, and mesh nebulizers. Table 1 summarizes the various nebulizers utilized to
aerosolize surfactants in clinical studies in infants.
Jet nebulizers, the oldest, most common, and affordable type, use a pressurized gas, the
“jet”, that passes through the liquid drug solution and shears droplets from the surface to
form the aerosol. There are many modifiable variables to jet nebulizer output, including the
density, pressure, and flow rate of the compressed gas, which influence the aerosol particle
size as well as variations in the arrangement of tubing and aerosol containment, allowing
continuous aerosol flow or medication release during inhalation only. Disadvantages to jet
nebulizers include their inefficiency as their reservoir tends to retain a large proportion of
medical solution [21–23].
Ultrasonic nebulizers use electrical input through a transducer that converts the energy
into high-frequency vibrations, creating a standing wave from which aerosolized droplets
are produced. In terms of surfactant administration, ultrasonic nebulizers have the major
drawback of heating the solution, presumptively leading to the denaturing of proteins, an
important component of effective surfactant [21,23].
Mesh nebulizers are the newest nebulizer device type, emerging as the nebulizer of
choice for new pharmaceuticals, distinguished by their efficiency [24]. This nebulizer also
uses an electric power source to create high-frequency vibrations to force the medication
solution through a fine mesh perforated by tapered holes, generating the aerosol. Variations
within this nebulizer class are primarily based on the parameters of the mesh: different
material composition of the mesh and varying diameters of the tapered hole openings,
containing a range (1000–4000) of holes across the mesh surface. The primary disadvantages
of this nebulizer type include blockages of the mesh holes, the difficulty of cleaning it, and
the higher cost of the machine compared to other nebulizer types [21–23].
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Table 1. Summary of aerosolized surfactants and nebulizers utilized in clinical studies in preterm infants.
Study Population (n) Nebulizer (Type) Interface Surfactant Dose Flow Particle Size Comparison Outcome
Jorch et al., 1994 28–35 wk GA (20) IntersurgicalRO252/ME (jet)
Modified
nasopharyngeal tube
placed behind soft palate
Beractant 150 mg/kg pertreatment 8 L/min <4 µm Pre/post treatment
Significant improvement
of A-a gradient, PaCO2,
and Silverman score
Berggren et al., 2000 27–34 wk GA(34) Aiolos
® (jet) Infant Flow System
®




No benefit in treatment
group









after treatment. 30–32 wk
GA infant intubation rate
lower than historic
control
Sood et al., 2019 24–36 wk GA(17)
Low Flow MiniHeart
(jet) Short binasal prongs Beractant
100–200 mg/kg per
treatment 2 L/min or less Not reported Pre/post treatment
Decrease in heart rate






mesh) Face mask (not specified) Poractant alfa
200 mg/kg per
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4. Delivery, Deposition, Distribution, and Dispersion of Aerosolized Surfactant
Aerosolized surfactant confronts unique challenges, overcoming deposition in the
upper airways and being distributed to the deepest segments of the lung and effectively
dispersed within gas-exchanging alveolar tissues. A considerable portion of a delivered
therapeutic surfactant dosage is known to be lost before a sufficient amount descends below
the alveolar ducts. As little as 1% to 14% of a dosage has been reported to reach the most
distal lung parenchyma [25,26]. However, a more recent report using a newborn piglet
model introduced atomization rather than nebulization [27]. Their investigational system
is a multilumen flexible catheter capable of delivering low airway flow simultaneously
with intermittent delivery of surfactant. The median particle size was 40–60 µm. Despite
the larger particle size, they demonstrated that 40% of the surfactant is distributed by
scintigram in the distal lung regions. They achieved a remarkable supraglottic delivery that
overcomes tracheal and large bronchial airway losses to deposition yet provided bilateral
lung distribution and alveolar space dispersion. To meet the challenges of surfactant
delivery as an aerosol, animal data and in-vitro models have revealed considerable insight
into the potential for it to become an effective therapeutic agent. Multiple variables
have been determined that provide guidelines for translational considerations in the
development and clinical application of aerosolized surfactant for infants (see Figure 1).
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4.1. Delivery of Aerosolized Surfactant
Aerosol delivery is dependent upon the different designs of the many nebulizing
devices currently available (see “Nebulizers” above, Table 1). In turn, for surfactant therapy,
the various nebulizers generate an aerosol with unique characteristics that are dependent
upon the dosage, synchrony with inspired breaths, and desired time for delivery. An
immediate goal of aerosolizing exogenous surfactant is to establish an effective supraglottic
delivery system in tandem with existing non-invasive ventilatory support and set the stage
for surfactant dose distribution to the multiple lobes of the lung. Recognizing that a major
portion of the delivered dose is lost to the deep pharyngeal fossa [25,26], an attempt should
be made to synchronize the delivery with a majority of spontaneous breaths. Delivery
of an aerosol requires consideration for the time needed to complete a dose. This is true
whether the delivery is a continuous application or delivery is in synchrony with either
mechanically inspired breaths or spontaneous inspiration. Reports of 20 min to 2 h for
completion of aerosol dose delivery leave much to be resolved as to the effectiveness [28,29].
Dosage amount per delivery, in milligrams of a phospholipid, varies from 50 to 200 mg/kg
in either animal or human subjects, but all have been shown to improve gas exchange as
the ultimate test of aerosolization success [11,30].
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4.2. Deposition of Aerosolized Surfactant
Much of an aerosolized dosage is lost in the airways due to the velocity of the air
stream and the impaction of the droplet against the walls of the trachea and bronchi.
Further loss is incurred with gravitational settling upon the ciliated epithelium of the
airways [31]. Particles or droplets may be swept proximal by the cilia, or they may be
adsorbed in the underlying mucus layer of the ciliated epithelium of the airways. Finally,
some dosage is discarded through the clearance action of resident airway macrophages.
4.3. Distribution of Aerosolized Surfactant
Aerosol distribution within the regions of the lung may be gravity-dependent or
non-gravity-dependent depending upon the position of the infant. Cunha-Goncalves et al.
have demonstrated the impact of subject position in a spontaneously breathing piglet
model. The lung dose distribution was higher in the prone position. The influence of
gravity was also demonstrated, with the highest dose distribution in the lateral decubitus
position for the dependent lung [32]. An immediate goal of aerosolization is to reach as
much of each lobe as possible with the surfactant dose. In patients with acute respiratory
distress, alternating areas of atelectasis will be factors limiting the effectiveness of an
aerosol. Asgharian et al. described a system of aerosol generation using a radiolabeled iron
chloride solution to identify lung regions and specific lobes in spontaneously breathing
adult rats [33]. They demonstrated distribution and dispersion throughout both lungs,
with the greatest concentration of the inhalant deep within peripheral lung parenchyma.
Airway flow has been established as an important factor affecting aerosolized sur-
factants. An optimal airway flow would minimize deposition in the upper airway and
enhance distribution to the deepest regions of the lung. At low gas flow, airway tur-
bulence is minimized and laminar gas flow optimized. Laminar airway flow has been
shown to enhance particle and droplet distribution [31]. Using catheter-based laboratory
models, Syedain et al. [34] demonstrated that with an air jet nebulizer (Microjet™), they
could achieve low airway flow and simultaneously generate surface-active small (4 µm)
particles/droplets of commonly used surfactant therapeutic agents. Both observations
support known optimization of surfactant distribution to the deepest regions of the lung.
Moreover, the clinical implications of their observations are that low airway pressures and
jet-nebulized aerosol would be compatible with pressure support mechanical ventilation
or non-invasive continuous positive pressure ventilation for preterm infants.
4.4. Dispersion of Aerosolized Surfactant
An additional goal for achieving adequate delivery of an aerosolized surfactant is to
gain sufficient dispersion of the dosage deep within the parenchymal lung tissue, resulting
in adequate and sustained gas exchange. To this end, Aramendia et al. offered compu-
tational, experimental modeling of a delivery system replicating a preterm infant [35].
Their findings served to confirm that adequate dispersion of aerosolized surfactant at
the alveolar level is dependent upon the properties of droplet size, airflow driving pres-
sure, and airflow velocity. A perfluorocarbon was used as a proxy for surfactant, and
an intratracheal catheter was used to instill a comparable infant surfactant dosage into a
droplet-sizing spectrometer. Their data revealed the ideal droplet size to be 3.97 to 4.08 µm
at 4 to 5 atm, approximating earlier work showing the optimum droplet size of 3–4 µm,
with slightly reduced size at increased driving pressure [34]. From these aerosol dynamics,
droplet size remains paramount in studies for maximal distribution and dispersion of a
surfactant dosage within lung tissues [30]. Moreover, Borghardt et al., in a review of the
pharmacokinetics of inhaled therapies for respiratory diseases, refer to an aerodynamic
droplet size of 0.5–5.0 µm as being critical for the delivery of any “lung-dose”, with the
greatest potential to be dispersed at the deepest levels of lung parenchyma [36]. Once a
fraction of the aerosolized surfactant has reached the lower airways, nearing the end of the
ciliated epithelium, it approaches the alveolar ducts. At this point, the remaining surfactant
dosage becomes the lung-dose, ready for transport and dispersal as lipid vesicles within
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the alveolar ducts and alveolar spaces. The lung-dose becomes one portion that remains
as aerosolized droplets and another portion that comes in contact with the air-surface
liquid interface. Maximizing the surfactant lung-dose will continue to be a clinical goal as
newer nebulizers are developed. Presently, means for monitoring lung-dose effect will rely
mainly on effective infant pulmonary gas exchange, but evolving lung ultrasound tech-
nology promises to add imaging for evidence of greater surfactant lung-dose distribution
and dispersion.
5. The Potential Benefit of Aerosolized Surfactant
The major upside of aerosolized surfactant is reducing the need for both intubation
and positive pressure ventilation. Adverse events from endotracheal intubations are com-
mon in neonates, with incidences ranging from ~20–40% [37,38]. Associated complications
include: physiologic changes such as hypoxemia and bradycardia [38–40]; oral, airway, and
esophageal trauma/injury [37,38,41]; or inappropriate surfactant administration [38,42].
Successful intubation often requires multiple attempts [42,43]; consequently, the higher
the number of attempts, the more the risk for adverse events [37], an important considera-
tion with the rising concern for endotracheal intubation proficiency among trainees and
providers [44–47]. In addition, positive pressure ventilation has well documented adverse
outcomes, especially in preterm infants [48,49]. Positive pressure ventilation early after
birth (even for a few breaths) causes lung injury and blunts the therapeutic effects of the
surfactant [50,51]. The initial injury is further exacerbated by continuous and prolonged
mechanical ventilation in the neonatal intensive care unit [52–58]. Other benefits of a nebu-
lized surfactant include avoiding the risks of sedation medications and paralytic agents,
often used for intubation in preterm infants [59].
It is unclear if there is a favorable cost–benefit of using aerosolized surfactants. The
human studies used high surfactant dosages to account for losses. The duration of admin-
istration of aerosolized surfactants is comparable and sometimes longer than surfactant
instillation strategies and, currently, not a major advantage. Finally, the recent clinical
studies that showed benefit from aerosolized surfactants did not include preterm infants
with severe RDS and lacked sufficient numbers of extremely preterm infants, an important
consideration for clinical implementation.
6. Conclusions
We presented a historical narrative of the progress seen in the application of aerosolized
surfactants over the past six decades. There is rising and promising evidence supporting
the use of aerosolized surfactant in preterm infants with mild to moderate RDS. However,
there is a paucity of data in infants with severe RDS and the smallest extremely preterm in-
fants. This movement of assessing aerosolized surfactants shows no signs of slowing, with
multiple ongoing national clinical trials [60–62]. We also summarized in this manuscript
the mechanisms of ideal aerosolization strategies, with a focus on delivery, distribution, de-
position, and dispersion when applied to the human lung. We believe these are important
concepts for neonatologists and clinicians to understand as we translate the evidence to
clinical practice in the future. Importantly, more studies are needed to optimize dosage,
nebulizer types, non-invasive interfaces, and synchronization before supporting wide use
in preterm infants. If an ideal surfactant aerosol can be advanced with non-invasive means
of ventilatory support and established efficacy and safety for newborn premature infants, a
major therapeutic step forward can be achieved in the near future.
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